KOL Insight

2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview

Following our live coverage of ASH, we interviewed a KOL who specializes in treating lymphoid malignancies to provide further insight on current and future paradigms for the treatment of CLL and NHLs.

Acne Prescribing Practices Pulse Survey

We performed a survey of 10 dermatologists currently practicing in the US to gauge

prescribing practices for the treatment of acne.

NASH KOL Insight Interview #1

The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold